Pall Opens New Life Sciences CoE in Shanghai
News Oct 17, 2013
Pall Corporation has inaugurated the Pall Life Sciences Centre of Excellence (CoE) at its new Zhangjiang site in Shanghai in the People’s Republic of China.
The new Centre of Excellence, which offers biopharmaceutical process solutions, technical and validation support as well as training, extends Pall’s local capabilities for its growing base of life sciences customers in the region.
“This year marks the 20th anniversary of Pall’s expansion into China. The opening of the Shanghai Life Sciences Centre of Excellence is another milestone in Pall’s development in China,” said Larry Kingsley, Chairman and CEO of Pall Corporation.
Kingsley continued, “The new Centre of Excellence not only reinforces our commitment to investing in the region, but also makes it easier for customers in the area to do business with us.”
The new CoE is fully equipped with the most advanced capabilities for process demonstration, testing and validation. Customers also can consult with Pall experts about equipment selection, installation and adjustment.
Integrated with the CoE at the Shanghai facility is a branch office that serves both the company’s Life Sciences and Industrial customers.
More than 200 employees work at the 8,600 m2 Shanghai facility, which provides filtration, separation and purification solutions for a range of industries. These include biopharmaceuticals, medical, food & beverage, process technologies, aerospace and microelectronics.
“China is an important market for Pall and long-term, favorable economic trends give us the confidence to continue development in the potentially high-growth region,” said Hang Gek Low, Vice President of Pall China.
Low continued, “The establishment of the Shanghai CoE enhances our ability to service customers in the area while enabling us to provide dedicated support for Chinese enterprises exploring overseas markets.”
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018